Design, synthesis and SAR of a series of 1,3,5-trisubstituted benzenes as thrombin inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 5, 2011, Pages 1536-1540

  Isaacs, Richard C A ^a   Newton, Christina L ^a   Cutrona, Kellie J ^a   Mercer, Swati P ^a   Payne, Linda S ^a   Stauffer, Kenneth J ^a   Williams, Peter D ^a   Cook, Jacquelynn J ^a   Krueger, Julie A ^a   Lewis, S Dale ^a   Lucas, Bobby J ^a   Lyle, Elizabeth A ^a   Lynch, Joseph J ^a   McMasters, Daniel R ^a   Naylor Olsen, Adel M ^a   Michener, Maria T ^a   Wallace, Audrey A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anticoagulant; Inhibitor; Thrombin

Indexed keywords

ACETAMIDE DERIVATIVE; AMINOPYRIDINONEACETAMIDE; BENZAMIDE; BENZAMIDE DERIVATIVE; BENZENE DERIVATIVE; DIPHENYL ETHER; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTICOAGULATION; ARTICLE; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYBRIDIZATION; IN VITRO STUDY; LIVER MICROSOME; NONHUMAN; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANTITHROMBINS; BENZENE; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN;

EID: 79951723419     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.12.105     Document Type: Article

References (19)

1. P.E.J. Sanderson, K.J. Cutrona, B.D. Dorsey, D.L. Dyer, C.M. McDonough, A.M. Naylor-Olsen, I.-W. Chen, Z. Chen, J.J. Cook, S.J. Gardell, J.A. Krueger, S.D. Lewis, J.H. Lin, B.J. Lucas Jr., E.A. Lyle, J.J. Lynch Jr., M.T. Stranieri, K. Vastag, J.A. Shafer, and J.P. Vacca Bioorg. Med. Chem. Lett. 8 1998 817
2. P.E.J. Sanderson, T.A. Lyle, K.J. Cutrona, D.L. Dyer, B.D. Dorsey, C.M. McDonough, A.W. Naylor-Olsen, I.-W. Chen, Z. Chen, J.J. Cook, C.M. Cooper, S.J. Gardell, T.R. Hare, J.A. Krueger, S.D. Lewis, J.H. Lin, B.J. Lucas, E.A. Lyle, J.J. Lynch, M.T. Stranieri, K. Vastag, Y. Yan, J.A. Shafer, and J.P. Vacca J. Med. Chem. 41 1998 4466
3. von der Saal, W.; Heck, R.; Kucznierz, R.; Leinert, H.; Stegmeier, K. Ger. Offen. DE 4430757 A1, 1996.
4. Lu, T.; Illig, C. R.; Tomczuk, B. E.; Soll, R. M.; Subasinghe, N. L.; Bone, R. F. PCT Int. Appl. WO 9711693 A1 1997.
5. Lu, T.; Tomczuk, B. E.; Illig, C.; Soll, R. M. PCT Int. Appl. WO 9724135 A1 1997.
6. Our involvement in this series was initiated based solely on the structures disclosed in the original patent applications in ref 2 above. After the work commenced, more information about compound 3 specifically (including its thrombin potency) and this series in general, was published. See: T. Lu, B. Tomczuk, C.R. Illig, R.F. Bone, L. Murphy, J. Spurlino, F.R. Salemme, and R.M. Soll Bioorg. Med. Chem. Lett. 8 1998 1595
7. T. Lu, B. Tomczuk, R. Bone, L. Murphy, F.R. Salemme, and R.M. Soll Bioorg. Med. Chem. Lett. 10 2000 83
8. T. Lu, R.M. Soll, C.R. Illig, R. Bone, L. Murphy, J. Spurlino, F.R. Salemme, and B.E. Tomczuk Bioorg. Med. Chem. Lett. 10 2000 79
9. B. Tomczuk, T. Lu, R.M. Soll, C. Fedde, A. Wang, L. Murphy, C. Crysler, M. Dasgupta, S. Eisennagel, J. Spurlino, and R. Bone Bioorg. Med. Chem. Lett. 13 2003 1495
10. R.C.A. Isaacs, M.G. Solinsky, K. Cutrona, C.L. Newton, A.M. Naylor-Olsen, J.A. Krueger, S.D. Lewis, and B.J. Lucas Bioorg. Med. Chem. Lett. 16 2006 338
11. M.B. Young, J.C. Barrow, K.L. Glass, G.F. Lundell, C.L. Newton, J.M. Pellicore, K.E. Rittle, H.G. Selnick, K.J. Stauffer, J.P. Vacca, P.D. Williams, D. Bohn, F.C. Clayton, J.J. Cook, J.A. Krueger, L.C. Kuo, S.D. Lewis, B.J. Lucas, D.R. McMasters, C. Miller-Stein, B.L. Pietrak, A.A. Wallace, R.B. White, B. Wong, Y. Yan, and P.G. Nantermet J. Med. Chem. 47 2004 2995
12. T.J. Tucker, S.F. Brady, W.C. Lumma, S.D. Lewis, S.J. Gardell, A.M. Naylor-Olsen, Y. Yan, J.T. Sisko, K.J. Stauffer, B.J. Lucas, J.J. Lynch, J.J. Cook, M.T. Stranieri, M.A. Holahan, E.A. Lyle, E.P. Baskin, I.-W. Chen, K.B. Dancheck, J.A. Krueger, C.M. Cooper, and J.P. Vacca J. Med. Chem. 41 1998 3210
13. W.C. Lumma, K.M. Witherup, T.J. Tucker, S.F. Brady, J.T. Sisko, A.M. Naylor-Olsen, S.D. Lewis, and R.M. Freidinger J. Med. Chem. 41 1998 1011
14. R. Kikumoto, Y. Tamao, K. Ohkubo, T. Tezuka, S. Tonomura, S. Okamoto, and A. Hijikata J. Med. Chem. 23 1980 1293
15. B. Kaiser, J. Hauptmann, A. Weiss, and F. Markwardt Biomed. Biochim. Acta 44 1985 1204
16. M. Reers, R. Koschinsky, G. Dickneite, D. Hoffmann, J. Czech, and W. Stuber J. Enzyme Inhib. 9 1995 61
17. F.A. Turner, and J.E. Gearien J. Org. Chem. 24 1959 1952
18. We consider human plasma 2 × APTT values of 1 μM or less to be generally predictive of good in vivo efficacy with lower concentrations being predictive of greater efficacy. We use this 1 μM mark routinely as a gate for determining whether to evaluate a compound further in vivo in the rat ferric chloride efficacy assay (see Ref. 4). In practice, in optimizing compounds, we strive to achieve 2 × APTT values of <0.5 μM.
19. For a discussion of the role of lipophilicity in modulating the functional potency of thrombin inhibitors see: T.J. Tucker, W.C. Lumma, A.M. Mulichak, Z. Chen, A.M. Naylor-Olsen, S.D. Lewis, R. Lucas, R.M. Freidinger, and L.C. Kuo J. Med. Chem. 40 1997 830